[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atherosclerotic-cardiovascular-disease-ascvd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atherosclerotic-cardiovascular-disease-ascvd":354},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,41,77,99,123,151,175,199,227,254,281,305,328],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100605073",false,"NCT07157774","Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event","MOVE-Lp(a)","Inclusion Criteria:\n\n* Have Lp(a) ≥175 nanomoles per liter (nmol\u002FL)\n* Meet one of the following criteria:\n\n  * Have had a prior atherosclerotic cardiovascular disease (ASCVD) event (such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body) within 10 years prior to screening\n  * Are at risk for a first ASCVD event, defined as one or more of the following:\n\n    * Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without a history of ASCVD event\n    * A high coronary artery calcium (CAC) score\n    * Reduced kidney function with diabetes\n    * Combination(s) of high risk factors\n\nExclusion Criteria:\n\n* Have experienced a major cardiovascular event or surgery, such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body, within 90 days prior to screening or occurring between screening and randomization\n* Are planning or expected to undergo a procedure to restore blood flow in the arteries or a major heart surgery during the study\n* Have uncontrolled high blood pressure\n* Have New York Heart Association (NYHA) class III or IV heart failure\n* Have undergone a procedure to remove cholesterol from the blood within 90 days of screening, or have a planned procedure during the study\n* Have severe kidney impairment\n* Have had cancer within 5 years prior to screening","ALL","18 Years",{"count":19,"type":20},10450,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.",[26,27],"Elevated Lp(a)","Atherosclerotic Cardiovascular Disease (ASCVD)","RECRUITING","2026-06-19",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":32},"2025-09-02",{"date":36,"type":20},"2031-03",{"name":38,"class":39},"Eli Lilly and Company","INDUSTRY",762,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100641620","NCT07654231","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)","RESOLVE-CKD","Inclusion Criteria:\n\n* Men and women aged 18-\\\u003C70 years of all race\u002Fethnicity groups\n* CKD stage 3 (estimated glomerular filtration rate (eGFR) \\>30 to 59 ml\u002Fmin\u002F1.73m2)\n* Urine albumin-to-creatinine ratio (uACR) ≥ 200 mg\u002Fg\n* Cardiac artery calcification (CAC) Agatston score ≥30\n* Hypertension, diabetes, dyslipidemia, or established atherosclerotic cardiovascular disease (ASCVD) (coronary artery disease (CAD), ischemic stroke, and peripheral artery disease), defined by self-report, ICD-10 codes, or the use of medications for these conditions.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Current Colchicine therapy\n* Hepatic disease\n* Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.\n* Immunosuppression\n* Current use of chemotherapy drugs or active cancer\n* Pregnancy\u002Fbreastfeeding\n* Hospitalized within the past 6 months\n* Allergic\u002Fintolerance to colchicine\n* Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir\u002Fritonavir, Saquinavir, Nelfinavir)\n* Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)\n* Human immunodeficiency virus (HIV) infection\n* Gout attack ≥ 1 time per year\n* Severe anemia (hemoglobin \\\u003C 8 g\u002Fdl for women and \\\u003C 9 g\u002Fdl for men)\n* eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2\n* uACR \\\u003C200 mg\u002Fg\n* White blood cell count (WBC) \\\u003C3.0 x109\u002FL\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 x Upper Limit of Normal (ULN)\n* Total bilirubin \\>2 x ULN\n* Glucose \\>300mg\u002Fdl\n* Uses nicotine products or other recreational drugs\n* Unable to read or speak English\n* Participant in other conflict clinical trial,\n* Unable to complete the study measurements\n* Unable to undergo to computed tomography (CT) or dual-energy X-ray absorptiometry (DXA) scans\n* Unsafe to participate in this study per investigator's judgement.","69 Years",{"count":50,"type":20},60,[52],"PHASE2","The overall objective of this pilot randomized clinical trial is to determine whether low-dose Colchicine (LoDoCo) improves vascular disease including vascular calcification, peripheral arterial disease (PAD), and chronic kidney disease-mineral and bone disorder (CKD-MBD) biomarkers in patients with chronic kidney disease (CKD) stage 3 over a 12-month intervention period, compared with usual care.\n\nSuccessful completion of this study will generate critical preliminary data to support a larger clinical trial aimed at evaluating inflammation-targeted therapies to mitigate CKD-MBD, including vascular calcification and related PAD, as well as osteoporosis, ultimately reducing cardiovascular events and mortality in patients with CKD. Additionally, this work has the potential to redefine the diagnostic framework for CKD-MBD.",[55,56,57,58,27,59],"Chronic Kidney Disease Mineral and Bone Disorder","Hypertension","Diabetes","Dyslipidemia","Chronic Kidney Disease (Stage 3)",[61,62,63,64],"Chronic Kidney Disease","CVD","vascular calcification","Colchicine","NOT_YET_RECRUITING","2026-06-17",{"date":68,"type":32},"2026-06-22",{"date":70,"type":20},"2026-07-01",{"date":72,"type":20},"2027-12-31",{"name":74,"class":75},"University of Texas Southwestern Medical Center","OTHER",1,{"id":78,"slug":4,"hasResults":10,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":4,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":95,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":97,"locationsCount":4},"100592996","NCT07000695","Managed Access Programs for TQJ230, Pelacarsen","Inclusion Criteria:\n\n1. An independent request was received from a licensed physician.\n2. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.\n3. The patient is not eligible or able to enrol in a clinical trial or continue participation in such trial.\n4. There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.\n5. The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).\n6. Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.\n7. Managed Access provision is allowed per local laws\u002Fregulations.","80 Years","EXPANDED_ACCESS","The purpose of this registration is to list Managed Access Programs (MAPs) related to TQJ230, pelacarsen",[86],"Atherosclerotic Cardiovascular Disease, ASCVD",[88,89,90,91,92,93],"MAP","Manage Access Program","TQJ230","Pelacarsen","Atherosclerotic Cardiovascular Disease","ASCVD","AVAILABLE",{"date":96,"type":32},"2026-06-18",{"name":98,"class":39},"Novartis Pharmaceuticals",{"id":100,"slug":4,"hasResults":10,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100578639","NCT06813911","Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD","A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)","ADD-VANTAGE","Key Inclusion criteria:\n\n* Male and female participants 18 to ≤80 years of age at Screening visit\n* Established ASCVD, defined as documented coronary heart disease (CHD), cerebrovascular disease (CVD), or peripheral arterial disease (PAD) at Screening visit\n* On stable dose of local guideline recommended lipid lowering therapy for at least 30 days prior to Screening visit\n* Participants must successfully complete the run-in period of background inclisiran treatment in order to be randomized\n* On standard of care (SoC) treatment for other CVD risk factors including hypertension and diabetes for at least 30 days prior to Randomization\u002FBaseline visit\n* Central laboratory reported Lp(a) ≥175 nmol\u002FL at Screening visit\n* Central laboratory reported LDL-C \\>70 mg\u002FdL (or \\>1.8 mmol\u002FL) at Screening visit\n\nKey Exclusion Criteria:\n\n* Prior treatment with inclisiran\n* Any other PCSK9 inhibitor (e.g., evolocumab, alirocumab) use within 4 months prior to Screening visit\n* Uncontrolled hypertension at Randomization\u002FBaseline visit\n* Heart failure New York Heart Association (NYHA) class IV at Screening visit or at Randomization\u002FBaseline visit (Day 1)\n* Triglycerides ≥400 mg\u002FdL at Screening visit\n* History of malignancy of any organ system within the past 5 years\n* Myocardial infarction, stroke or other major bleeding, coronary or lower limb re vascularization, major cardiac or non-cardiac surgery between Screening visit and Randomization\u002FBaseline visit (Day 1)\n* Central laboratory reported platelet count \\\u003C140,000 per mm3\n* Active liver disease or hepatic dysfunction at Screening visit\n* Significant kidney disease at Screening visit\n* Pregnant or nursing women at Screening visit\n* Any uncontrolled chronic or serious medical condition which may pose an immediate risk to clinical stability of the study participant at Screening visit\n\n  * Other protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":107,"type":20},340,[23],"The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C).",[27],[112,113,93,114],"Lipoprotein(a)","cardiovascular disease","pelacarsen (TQJ230)","2026-06-15",{"date":66,"type":32},{"date":118,"type":32},"2025-04-30",{"date":120,"type":20},"2028-02-29",{"name":98,"class":39},95,{"id":124,"slug":4,"hasResults":10,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":76},"100637372","NCT07581808","Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention","PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary Prevention","PCSK9-DUO","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Established atherosclerotic cardiovascular disease (secondary prevention), defined as prior cardiovascular events or imaging-confirmed atherosclerosis (e.g., coronary artery disease on angiography or CT, carotid plaque on ultrasound, or peripheral arterial disease).\n* Eligible for PCSK9 inhibitor therapy according to national clinical criteria\n* Fasting LDL cholesterol ≥2.5 mmol\u002FL and ≤5.0 mmol\u002FL at screening\n* Documented statin intolerance or contraindication to statin therapy\n* On stable background lipid-lowering therapy (including ezetimibe if applicable) for at least 4 weeks prior to enrollment\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Eligibility for PCSK9 inhibitor therapy solely based on elevated lipoprotein(a) \\>1000 mg\u002FL with LDL-C below inclusion threshold\n* Prior use of any PCSK9 inhibitor (alirocumab, evolocumab or inclisiran) before enrollment\n* Planned initiation or modification of lipid-lowering therapy during the study period\n* Known homozygous familial hypercholesterolemia\n* Active liver disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3× upper limit of normal\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* Active malignancy or life expectancy \\\u003C1 year\n* Pregnancy, breastfeeding, or women of childbearing potential not using effective contraception\n* Known hypersensitivity to inclisiran, alirocumab, or any of their excipients\n* Participation in another interventional clinical trial within 30 days prior to enrollment\n* Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results",{"count":50,"type":20},[132],"PHASE4","This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.\n\nLowering low-density lipoprotein cholesterol (LDL-C) is essential to reduce the risk of cardiovascular events. While PCSK9 inhibitors are effective, many patients treated with a single agent do not reach recommended LDL-C targets, especially those who cannot take statins.\n\nInclisiran and alirocumab reduce LDL-C through different mechanisms. Inclisiran decreases the production of PCSK9 in the liver, while alirocumab binds circulating PCSK9 in the blood. Combining these therapies may lead to a greater reduction in LDL-C levels.\n\nIn this randomized, open-label clinical trial, approximately 60 patients in secondary prevention will be assigned to one of three groups: inclisiran alone, alirocumab alone, or a combination of both treatments. Patients will be followed for 9 months with regular clinical and laboratory assessments.\n\nThe main goal of the study is to determine whether combination therapy leads to greater LDL-C reduction compared to each treatment alone. Secondary objectives include assessing the proportion of patients achieving target LDL-C levels and evaluating treatment safety and tolerability.",[135,27],"Hypercholesterolemia",[137,138,139,140,141],"Alirocumab","Inclisiran","LDL cholesterol","Secondary prevention","Statin intolerance","2026-05-28",{"date":144,"type":32},"2026-06-02",{"date":146,"type":32},"2026-05-18",{"date":148,"type":20},"2027-06",{"name":150,"class":75},"University Medical Centre Ljubljana",{"id":152,"slug":4,"hasResults":10,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":76},"100640955","NCT07615296","Target-Oriented Strategy of Ultra-Low LDL-C (\u003C1.0 vs. 1.0-1.39 mmol\u002FL) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment","Target-Oriented Strategy of Ultra-Low LDL-C Goal in Extreme-High-Risk ASCVD Patients (\u003C1.0 vs. 1.0-1.39 mmol\u002FL): Clinical Benefit, Safety and Cost-Effectiveness Assessment- A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint Adaptive Trial","TARGET-EXTREME","Inclusion Criteria:\n\n1. Aged 18-80 years, any sex.\n2. Diagnosed with ultra-high-risk ASCVD per 2023 Chinese Lipid Guidelines: either ≥2 major ASCVD events within 24 months, or 1 major ASCVD event plus ≥2 high-risk factors (diabetes, multi-vessel disease, premature CHD family history, elevated Lp(a), hypertension).\n3. LDL-C ≥1.0 mmol\u002FL after ≥4-week maximum-tolerated statin plus ezetimibe therapy, confirmed by central laboratory.\n4. Able to complete follow-up and examinations; no severe hepatic\u002Frenal dysfunction.\n5. Voluntary participation with written informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity or intolerance to statins, ezetimibe, or PCSK9 inhibitors.\n2. Hemorrhagic stroke, active bleeding, severe trauma or major surgery within 6 months before enrollment.\n3. Malignancy (expected survival \\\u003C3 years), severe liver\u002Fkidney disease, or autoimmune disease.\n4. Cognitive impairment (MoCA \\\u003C20) or psychiatric disorders precluding assessment cooperation.\n5. Pregnant, breastfeeding, or planning pregnancy during the trial.\n6. Participation in other clinical trials or use of other lipid-lowering drugs within 3 months.\n7. Poor compliance or other conditions judged by investigators to interfere with the study.",{"count":159,"type":20},6000,[161],"NA","The goal of this clinical trial is to learn whether an ultra-low LDL-C target (\\\u003C1.0 mmol\u002FL) can improve clinical outcomes compared with a moderately low LDL-C target (1.0-1.39 mmol\u002FL) in Chinese patients with extreme-high-risk atherosclerotic cardiovascular disease (ASCVD). It also aims to evaluate long-term safety and cost-effectiveness, and explore potential benefit subgroups and underlying mechanisms. The main questions it aims to answer are:\n\nDoes an LDL-C target \\\u003C1.0 mmol\u002FL reduce major adverse cardiovascular events (MACE-4: cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, urgent coronary revascularization) compared with a target of 1.0-1.39 mmol\u002FL?What are the long-term safety risks including cognitive decline, hemorrhagic stroke, new-onset diabetes, new malignancies and severe adverse drug reactions under different LDL-C targets?Researchers will compare participants receiving an LDL-C target \\\u003C1.0 mmol\u002FL with those receiving a target of 1.0-1.39 mmol\u002FL to see if the ultra-low LDL-C strategy provides better clinical benefit with acceptable safety and economic value.\n\nParticipants will:\n\nReceive lipid-lowering therapy following a mandatory titration-maintenance-off-target correction algorithm according to their assigned LDL-C target Undergo routine follow-up every 3 months, cognitive assessment every 6 months, and comprehensive annual re-examinations for a median of 2 years and up to 5 years Have centralized blinded lipid testing and endpoint adjudication by an independent Clinical Event Committee",[27],[165],"Extreme-high-risk ASCVD, LDL-C target, Ultra-low LDL-C, Lipid-lowering therapy","2026-05-23",{"date":168,"type":32},"2026-05-29",{"date":170,"type":20},"2027-01-01",{"date":172,"type":20},"2031-12-31",{"name":174,"class":75},"Beijing Anzhen Hospital",{"id":176,"slug":4,"hasResults":10,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100620305","NCT07355894","Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)","Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in AtheroSclerotic CardioVascular Disease (HEARTWISE-ASCVD) Study","HEARTWISE","Inclusion Criteria:\n\n* Non-gated chest CT performed within the prior 2 years within the health system\n* Active health system engagement with an affiliated clinician eligible for notification, defined as ≥1 clinical visit within the prior 2 years AND at least one of the following:\n\n  1. Active enrollment in the site's integrated healthcare plan (e.g., Kaiser Permanente Northern California), OR\n  2. LDL-C measured within the health system within the prior 2 years, OR\n  3. Outpatient cardiovascular medication prescription within the prior year\n* Meets one of the following clinical criteria:\n\n  1. Clinical ASCVD diagnosis (coronary artery disease, peripheral arterial disease, or ischemic cerebrovascular disease) AND AI-detected CAC \\>0 on non-gated chest CT, OR\n  2. No ASCVD diagnosis AND AI-detected CAC ≥100\n* Suboptimal LDL-C control, defined as either: Last LDL-C ≥70 mg\u002FdL in the last 2 years, OR No LDL-C measurement in the last 2 years\n\nNote: Site-level variations and additional refinements may occur based on local stakeholder input and patient population identification.\n\nExclusion Criteria:\n\n* Dementia\n* Heart transplant\n* Active hospice\n* Other life-limiting illness as determined by the site investigator (e.g., metastatic cancer)\n* Additional participant-level exclusions as determined by clinical stakeholders at each site","74 Years",{"count":184,"type":20},120000,[161],"This multi-site study will test whether an opportunistic AI-based CAC screening and notification intervention can improve cholesterol treatment and lower cholesterol levels in adults. The study uses artificial intelligence to detect calcium buildup in heart arteries (coronary artery calcium or CAC) on chest CT scans that patients have already had for other reasons. The study will focus on adults who either have known atherosclerotic cardiovascular disease (ASCVD) or have significant calcium buildup (a CAC score of 100 or higher), and whose cholesterol is not well controlled.\n\nIt will also evaluate how well this approach can be implemented at scale across multiple health systems. The main questions it aims to answer are:\n\nDoes notifying patients and their clinicians about incidental CAC increase lipid-lowering therapy(LLT) initiation or intensification?\n\nDoes the intervention improve Low-Density Lipoprotein(LDL)-cholesterol control and related lipid testing?\n\nHow does the intervention affect downstream care (e.g., clinic visits, cardiology referrals, and cardiac testing)?\n\nResearchers will use an FDA-cleared AI algorithm to quantify CAC on previously performed non-gated chest CT scans and identify eligible participants through the electronic health record. Participants will be randomized to receive CAC notification either right away or after a 6-month delay.",[27,188],"Coronary Artery Calcification","2026-04-17",{"date":191,"type":32},"2026-04-22",{"date":193,"type":20},"2026-05",{"date":195,"type":20},"2028-03",{"name":197,"class":75},"Stanford University",6,{"id":200,"slug":4,"hasResults":10,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":10,"sex":16,"minAge":206,"maxAge":4,"enrollmentInfo":207,"targetDuration":209,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":225,"locationsCount":76},"100634682","NCT07542860","Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients","Risk Assessment and Application of Antithrombotic Therapy in Elderly Patients With Cardiovascular Disease: A Multicenter, Prospective Cohort Study","LAPIS","Inclusion Criteria:\n\n1. Age ≥ 60 years.\n2. Diagnosis of established atherosclerotic cardiovascular disease (ASCVD), including acute coronary syndrome, stable coronary artery disease, post-revascularization (percutaneous coronary intervention or coronary artery bypass grafting), ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, or peripheral artery disease.\n3. Long-term use of aspirin (≥1 year) for secondary prevention of ASCVD.\n4. Available laboratory tests (within the past 3 months): complete blood count, urinalysis, routine stool examination and occult blood test, liver and kidney function, electrolytes, glucose, lipids, uric acid, coagulation function, etc.\n5. Willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity to aspirin or other salicylates, or any other component of the drug product; history of asthma induced by salicylates or nonsteroidal anti-inflammatory drugs (NSAIDs), or any other condition that, in the clinical judgment, makes the patient unsuitable for study participation.\n2. Life expectancy ≤ 2 years due to non-cardiovascular causes.\n3. Poor compliance (unable to adhere to prescribed medication or follow scheduled follow-up visits as judged by the investigator).","60 Years",{"count":208,"type":20},5448,"3 Years","OBSERVATIONAL","Elderly patients with cardiovascular disease face a high risk of both thrombotic and bleeding events when receiving antithrombotic therapy. The optimal dose of aspirin for secondary prevention in this population remains uncertain, particularly in Chinese elderly individuals. This multicenter, prospective cohort study aims to evaluate the effectiveness and safety of a lower dose of aspirin (50 mg daily) compared with the standard dose (100 mg daily) for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in Chinese patients aged 60 years and older. The study is an extension of the existing LAPIS cohort (ChiCTR1900021980), which has enrolled 5,448 participants receiving long-term aspirin for secondary prevention. Participants will be followed for an additional 2 years (total follow-up up to approximately 6 years) through telephone, clinic visits, and electronic medical records. The primary effectiveness outcome is the first occurrence of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, unstable angina, need for revascularization, non-fatal stroke, transient ischemic attack, and cardiovascular death (excluding intracranial bleeding). The primary safety outcome is the first occurrence of bleeding events (classified by BARC criteria). A secondary aim is to develop and validate a risk prediction model (nomogram) for thrombotic and bleeding events specifically for elderly Chinese patients receiving antithrombotic therapy, using LASSO regression and Cox proportional hazards models. The study will provide real-world evidence to guide individualized antithrombotic management in the aging Chinese population.",[27,213,214],"Secondary Prevention","Cardiovascular Diseases",[216,213,214,217,218],"Aspirin","Aged","Risk Assessment","2026-04-14",{"date":221,"type":32},"2026-04-21",{"date":223,"type":32},"2019-04-10",{"date":72,"type":20},{"name":226,"class":75},"Peking University First Hospital",{"id":228,"slug":4,"hasResults":10,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":10,"sex":16,"minAge":234,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":253},"100589937","NCT06960902","Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)","Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia","ATHERO-FH","Inclusion Criteria:\n\n* Person willing to sign the study consent form\n* Person affiliated with a current social security scheme\n* Person with a definite diagnosis of Familial Hypercholesterolemia, defined by a Dutch Lipid Clinic Network (DLCN) clinical-biological score \\> 8 and\u002For an identified causal mutation in the LDL receptor (LDLR) gene, apolipoprotein B100 gene, PCSK9 gene, or apolipoprotein E gene\n* Male aged 40 years or older, or female aged 50 years or older\n* Ability to understand French for questionnaire completion\n* Person not taking any lipid-lowering medication or on a stable dose of lipid-lowering therapy for at least one month prior to inclusion (three months for PCSK9 inhibitors) at Visit 1\n* Person not taking any antihypertensive medication or on a stable dose of antihypertensive therapy for at least one month at Visit 1\n* Person not taking any antidiabetic medication or on a stable dose of antidiabetic therapy for at least 3 months at Visit 1\n\nExclusion Criteria:\n\n* Subject with a technical contraindication for coronary CT scan: patient diameter \\> 70 cm and\u002For weight \\> 250 kg\n* Patient with a history of atherosclerotic cardiovascular event (myocardial infarction, ischemic heart disease, coronary revascularization, ischemic stroke, carotid endarterectomy, lower limb arterial revascularization)\n* Patient allergic to iodinated contrast agents\n* Severe renal insufficiency: estimated glomerular filtration rate (eGFR) according to the CKD-EPI formula ≤ 30 ml\u002Fmin\n* Subject with active cancer or in remission for less than 3 years\n* Subject who has received oral or intravenous corticosteroid therapy within the last 6 months\n* Subject with untreated or poorly controlled hypothyroidism\n* Subject receiving immunosuppressive or anticancer therapy\n* Subject refusing to participate\n* Subject under guardianship, curatorship, or judicial protection, or without social insurance coverage\n* Pregnant woman","40 Years",{"count":236,"type":20},600,[161],"The goal of this study (interventional clinical research not involving a health product) is to assess the prevalence of subclinical coronary atherosclerosis diagnosed by coronary CT angiography in heart failure patients in primary prevention, across different levels of cardiovascular risk defined by coronary artery calcium (CAC) score percentiles (based on data from the MESA study): low risk (≤25th percentile for age, sex, and ethnicity), intermediate risk (25th \\\u003C CAC ≤ 75th percentile), and high risk (\\>75th percentile). The Patients will attend an on-site visit at inclusion (and must undergo a coronary CT angiography within 6 months following this visit), will be contacted by phone at 1 year and 2 years, and will return for an on-site visit at 30 months.",[240,27],"Familial Hypercholesterolemias",[242,243],"Familial hypercholesterolemia","atherosclerotic cardiovascular disease","2026-03-16",{"date":246,"type":32},"2026-03-19",{"date":248,"type":32},"2025-09-25",{"date":250,"type":20},"2029-09-25",{"name":252,"class":75},"Nantes University Hospital",9,{"id":255,"slug":4,"hasResults":10,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":10,"sex":16,"minAge":261,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":5},"100587630","NCT06930885","Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","Evaluation of a POlypill and Colchicine for Risk Reduction in Patients With Established Atherosclerotic Cardiovascular Disease: The EPOCA Randomized Clinical Trial","EPOCA","Inclusion Criteria:\n\n* Individuals aged ≥ 45 years AND\n* Signature of the Informed Consent Form (ICF) AND at least one of the following criteria:\n* Previous atherothrombotic cardiovascular event (acute coronary syndrome, ischemic stroke, high-risk transient ischemic stroke, acute limb ischemia\u002Farterial occlusion, or non-traumatic limb amputation) AND\u002FOR\n* Previous arterial revascularization (percutaneous, surgical, and\u002For hybrid) OR\n* Diagnosis of significant atherosclerotic disease with ≥ 50% obstruction in any arterial territory (coronary, cerebrovascular, or peripheral), in the absence of a prior cardiovascular event or arterial revascularization.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Women of childbearing age who do not use any form of contraception;\n* Known history of chronic kidney disease, stage ≥ 4 (estimated glomerular filtration rate ≤ 30 mL\u002Fmin, if available);\n* Known history of cirrhosis or severe liver disease (e.g., transaminase levels \\> 3 times the upper limit of normal, if available);\n* Known history of inflammatory muscle disease (e.g., dermatomyositis or polymyositis) or creatine phosphokinase (CPK) levels \\> 3 times the upper limit of normal, if available);\n* Known history of moderate or severe valvular heart disease with anticipated need for valvular intervention within the next 12 months;\n* Planned arterial revascularization (inclusion is possible 30 days after completion of all planned procedures);\n* Left ventricular ejection fraction ≤40% (with the exception of patients with documented intolerance to ACE inhibitors and\u002For sacubitril\u002Fvalsartan, who remain eligible for study enrollment);\n* Heart failure with functional class ≥ III according to the New York Heart Association (NYHA), regardless of left ventricular ejection fraction;\n* Blood pressure \\\u003C 120\u002F80 mmHg in the absence of antihypertensive therapy;\n* Life expectancy ≤ 12 months;\n* Acute arterial event (acute coronary syndrome, non-cardioembolic ischemic stroke, acute limb ischemia) in the past 30 days;\n* Substance abuse\u002Falcoholism;\n* Psychiatric and\u002For neurodegenerative disorder limiting self-care capacity;\n* Concurrent participation in another randomized clinical trial;\n* Contraindication to any component of the polypill;\n* Current or planned use of oral anticoagulant therapy within the next 12 months (except rivaroxaban 2.5 mg twice daily for patients with peripheral artery disease);\n* High risk of bleeding (e.g., but not limited to: blood dyscrasias, hemophilia, previous gastrointestinal or central nervous system bleeding);\n* Contraindication to colchicine;\n* Current use of colchicine.","45 Years",{"count":263,"type":20},7713,[23],"The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.",[267,27],"Atherothrombotic Diseases",[269,270,271,64],"Atherothrombotic diseases","Atherosclerotic cardiovascular disease","Polypill","2026-01-21",{"date":274,"type":32},"2026-01-22",{"date":276,"type":32},"2025-06-12",{"date":278,"type":20},"2031-05",{"name":280,"class":75},"Hospital do Coracao",{"id":282,"slug":4,"hasResults":10,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":10,"sex":16,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":291,"studyType":210,"phases":4,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":76},"100617236","NCT07315997","The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study","CAT-RA","Inclusion Criteria:\n\n* RA diagnosed by a rheumatologist\n* Age 40- 79\n* ≥1 ASCVD risk factor including prediabetes, hypertension, BMI \\>30, current or history of cigarette smoking\n\nExclusion Criteria:\n\n* Patients on a statin or with a contraindication to statin, on a cholesterol absorption inhibitor, or on a PCSK9 inhibitor\n* Patients with diabetes mellitus\n* Pregnancy","35 Years","79 Years",{"count":290,"type":20},120,"2 Years","Individuals with rheumatoid arthritis (RA) have up to 2x the risk of having a heart attack compared to someone without RA. The goal of this study is to identify biomarkers that can help us do a better job of identifying individuals at risk before they develop symptoms of heart disease and start preventative treatment earlier.",[294,27],"Rheumatoid Arthritis (RA",[285],"2025-12-31",{"date":298,"type":32},"2026-01-05",{"date":300,"type":32},"2024-09-04",{"date":302,"type":20},"2028-03-04",{"name":304,"class":75},"Brigham and Women's Hospital",{"id":306,"slug":4,"hasResults":10,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":10,"sex":311,"minAge":17,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":21,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":4},"100616878","NCT07311330","Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction","A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction","Inclusion Criteria:\n\n1. Fully understand the purpose, nature, method and possible adverse reactions of the study, voluntarily participate as a subject in the study, and sign the informed consent form (ICF) before performing any study-related assessments;\n2. One or both of the previous history of coronary atherosclerosis, coronary heart disease, cerebral atherosclerosis, stroke, ischemic attack, carotid atherosclerosis, peripheral arterial disease, or plaque in at least one vessel of the carotid, subclavian, or femoral arteries as detected by peripheral arterial ultrasound .\n3. Clinical diagnosis of mild to moderate erectile dysfunction, IIEF-5 questionnaire score ≤ 21 points, duration of at least 3 months (subject to signing informed consent);\n4. Subjects (including partners) guarantee that they have no plans to father a child or donate sperm during the study and for 3 months after the last dose and voluntarily take appropriate contraceptive measures;\n5. After the screening run-in period, the following three conditions were met simultaneously:\n\n1\\) At least 4 attempts at sexual intercourse during the run-in period; 2) Has a failure rate of ≥ 50% of attempts to intercourse (failure to intercourse is defined as having at least one of the three questions answered on the SEP); 3) IIEF-EF score ≥ 11 and ≤ 25.\n\nExclusion Criteria:\n\n1. Patients with erectile dysfunction caused by other sexual dysfunction diseases (such as ejaculatory dysfunction) or endocrine diseases that are not controlled (after medication) (such as hypogonadism, hyperthyroidism\u002Fhypothyroidism, pituitary tumor, etc.);\n2. History of stroke within 6 months prior to informed consent;\n3. Patients who have received or are receiving anti-androgen therapy, or have a history of androgen replacement therapy and are stable for less than 3 months;\n4. Patients scheduled for CABG, PCI, heart transplantation, SAVR\u002FTAVR during the study period;\n5. Patients with unstable diabetic blood glucose control, and fasting blood glucose more than 15 mmol\u002FL, or accompanied by diabetic complications (diabetic nephropathy, peripheral neuropathy);\n6. Combined with abnormal liver function, defined as AST and\u002For ALT more than 2 times the upper limit of normal;\n7. Combined with severe renal dysfunction, defined as glomerular filtration rate \\\u003C 30.0 mL\u002Fmin\u002F1.73m ² calculated by CKD-EPI formula;\n8. Subjects who have used vacuum aspiration (VCD), intracavernosal injection (ICI) therapy or other drugs to treat erectile dysfunction and cannot interrupt the above treatment during the study;\n9. Patients who have severe central nervous system injury (cerebral vascular diseases such as cerebral hemorrhage or ischemia, brain inflammatory diseases such as encephalitis or meningitis, craniocerebral trauma or spinal cord injury), or peripheral nervous system injury or lesions within 6 months before signing the informed consent;\n10. History of myopathy\u002Fmyalgia, or susceptibility to myopathy\u002Frhabdomyolysis (e.g., family history of hereditary myopathy, previous use of HMG-CoA reductase inhibitors in combination with fibrates, etc.);\n11. Presenting with hypothyroidism, defined as marked TSH elevations (usually \\> 1.5 ULN) associated with decreases in free T4 (FT4) ;\n12. Patients with a history of drug abuse, drug abuse and alcoholism (tolerance, withdrawal, impaired control of drinking behavior) in the past 1 year;\n13. Participation in another interventional clinical investigator within 1 month prior to informed consent;\n14. Patients who, in the opinion of the investigator, are not suitable for this study.","MALE","75 Years",{"count":314,"type":20},40,[52],"This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction",[27,318],"Erectile Dysfunction","2025-12-21",{"date":321,"type":32},"2025-12-30",{"date":323,"type":20},"2026-01-31",{"date":325,"type":20},"2026-11-14",{"name":327,"class":39},"Beijing Inno Medicine Co., Ltd.",{"id":329,"slug":4,"hasResults":10,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":334,"targetDuration":291,"studyType":210,"phases":4,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":76},"100608959","NCT07208331","Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management","TELE-CVRM","Inclusion Criteria:\n\n* Age ≥18 years\n* All patients enrolled in the program (high-risk and very high-risk patients)\n\nExclusion Criteria:\n\n* Not able to provide informed consent\n* No access to smartphone and\u002For tablet\n* Inability to use digital tools required for the program",{"count":335,"type":20},750,"The goal of this observational study is to evaluate the implementation of a structured, digital, nurse-led, remote monitoring care pathway for cardiovascular risk management (CVRM). Participants will receive this care as part of routine clinical practice. In addition to standard follow-up, participants will complete questionnaires on quality of life, medication adherence, system usability, and patient satisfaction.",[27,56,58],[339,340,341,342,343,344,345],"Telemonitoring","Lipids","eHealth","Screening","Telemedicine","Risk factor management","Blood pressure","2025-10-02",{"date":348,"type":32},"2025-10-06",{"date":348,"type":20},{"date":351,"type":20},"2030-10-01",{"name":353,"class":75},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",""]